

**PATENTS** 



## IN THE UNITED STATES PATENT AND TRADMARK OFFICE

ants: Henkin, et al.

Serial No.: 10/764,379

Filed: January 23, 2004

Title: PEPTIDE ANTIANGIOGENIC

**DRUGS** 

1

Case No.: 6356USC1

Group Art No.: 1654

Examiner: Lukton, David

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Mail Stop Amendment Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450 on:

Date of Deposit: January 18, 2006

Tanva Parent

Date

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## TRANSMITTAL LETTER

Dear Sir:

Enclosed herewith for the patent application identified above entitled PEPTIDE ANTIANGIOGENIC DRUGS are the following:

- 1. Response to Office Action (2 Pages); and
- 2. Return Receipt Postcard

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR §1.16, as well as any patent application processing fees under 37 CFR §1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025.

ABBOTT LABORATORIES

Customer Number 23492 Telephone: (847) 935-7956 Facsimile: (847) 938-2623 Respectfully submitted, Henkin, et al.

Henkin, et ai

Johanna M. Corbin Registration No. 51,582

Attorney for Applicants



**PATENT** 

Applicants: Henkin, et al.

Serial No.: 10/764,379

Filed: January 23, 2004

Title: PEPTIDE ANTIANGIOGENIC

**DRUGS** 

Case No.: 6356USC1

Mail Stop Amendment Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

Group Art No.: 1654

Examiner: Lukton, David

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 on:

Date of Deposit: January 18, 2006

## RESPONSE TO RESTRICTION REQUIREMENT

The following is in response to the Office Action mailed on December 30, 2005.

The Examiner has required restriction of the application to one of the groups of claims under 35 U.S.C. § 121. The Applicants, by their attorney, elected the claim of Group IV (claims 15 and 17) and Example 14 of the specification in their response dated December 8, 2005. Applicants did not elect a specific disease to be treated; therefore, in response to the notice of December 30, 2005, Applicants hereby specify their election for the treatment of cancer. For the convenience of the examiner, the species of Example 14 is reproduced below.

N-Ac-Sar-Gly-Val-D-allolle-Thr-Nva-Ile-Arg-ProNHCH<sub>2</sub>CH<sub>3</sub>

Favorable action is now solicited. Applicants reserve the right to file divisional applications on all non-elected subject matter of the instant application.

Respectfully submitted, Henkin, et al.

ABBOTT LABORATORIES Customer Number 23492

Telephone: (847) 935-7956 Facsimile: (847) 938-2623

Johanna M. Corbin Registration No. 51,582 Attorney for Applicants